Pradžia › Difuzinė didelė B ląstelių limfoma › Utah
Difuzinė didelė B ląstelių limfoma klinikiniai tyrimai Utah
14 tyrimai dėl Difuzinė didelė B ląstelių limfoma ieško dalyvių vietose Utah.
Miestai Utah
Oficialus tyrimo tekstas (anglų kalba)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- Intermountain Health LDS Hospital, Salt Lake City
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06500273A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Community Cancer Trials of Utah, Ogden
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06091865A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Intermountain Medical Center ( Site 0182), Murray
- Intermountain Healthcare - St. George ( Site 0203), St. George
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06890884A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Intermountain Healthcare, Salt Lake City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
- Huntsman Cancer Institute, Salt Lake City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-26 · NCT06227026Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Intermountain Healthcare, Salt Lake City
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-04 · NCT07188558Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-10 · NCT05077527External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-04 · NCT07528352A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-20 · NCT04830137Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-13 · NCT04775745Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-10-20 · NCT05890352Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2024-09-26 · NCT06238648Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.